Combination Treatments to the Huge Ovarian Cancer with Liver Metastases

• Published in: Gan to kagaku ryoho Vol. 44; no. 12; p. 1535
• Main Authors: Hasuike, Yasunori, Kanaoka, Yasushi, Higuchi, Ichiro, Imoto, Hirosumi, Hosomi, Sanae, Ishikawa, Akira, Akiyama, Yosuke, Tanigawa, Takahiko, Miyamoto, Makoto
• Format: Journal Article
• Language: Japanese
• Published: Japan 01.11.2017
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Catheter Ablation; Combined Modality Therapy; Female; Humans; Liver Neoplasms - secondary; Liver Neoplasms - surgery; Middle Aged; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Ovarian Neoplasms - surgery; Paclitaxel - administration & dosage
• ISSN: 0385-0684

We report a CR case of huge ovarian cancer with peritoneal and liver metastases who was operated bilateral ovaries, uterus and peritoneal metastases at first, followed by systemic chemotherapy and performed 4 times of radiofrequency ablation (RFA)and 2 times of liver resection(LR). The case was a 50-year-old woman. She suffered with bowel enlargement from over 1 year ago. Preoperative MRI finding was huge ovarian serous cyst with partial solid tumor inside. The major axis was about 30 cm. CA125 and CA19-9 levels were elevated. Tumor reduction surgery was performed with bilateral salpingooophorectomy and hysterectomy with resecting peritoneal metastatic lesions. Postoperative systemic chemotherapy(carbo- platin 550mg/day 1 plus paclitaxel 130mg/day 1, 8, 15)(CBDCA plus PTX)were performed amount 6 courses. Unfortu- nately liver metastases at S3, S4, S6, S7 and S8/5 appeared about 7months after operation.We restarted the CBDCA plus PTX therapy from 15 months after operation when the tumor maker elevated. After 18 courses of CBDCA plus PTX therapy liver metastases remained only at S3. But gradually tumors grew up and size of tumors increased in spite of 3 more courses of CBDCA plus PTX therapy. So we challenged 2 times of RFA at S8/5 metastases that grew most rapidly and the values of increasing tumor makers stopped elevating. Then we performed LR at S3 and S4 metastases and the values of tumor makers returned to the normal level. But next S6 and S7 metastases appeared, we chose the RFA at first. At last recurrence of S7 was resected and all of liver metastases were treated. We checked no peritoneal metastases twice at the time of operation. The values of tumor makers became the normal level. Now she is alive well without metastases over 6 years after first operation. RFA and LR were effective at liver metastases from ovarian cancer that became resistant to systemic chemotherapy.